• 1. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 2. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833
• 3. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696
• 4. Fate of nitrogen-15 in the subsequent growing season of greenhouse tomato plants (Lycopersicon esculentum Mill) as influenced by alternate partial root-zone irrigation
  Maomao Hou,Fenglin Zhong,Qiu Jin,Enjiang Liu,Jie Feng,Tengyun Wang,Yue Gao RSC Adv., 2017,7, 34392-34400
• 5. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147

Recent Advances in the Study of 2-Fluoro-N-hydroxypyridine-4-carboxamide (CAS: 1880041-66-6)

2-Fluoro-N-hydroxypyridine-4-carboxamide (CAS: 1880041-66-6) is a small molecule compound that has garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential therapeutic applications. Recent studies have focused on its role as a selective inhibitor of specific enzymatic pathways, particularly those involved in inflammatory and oncogenic processes. This research brief aims to synthesize the latest findings on this compound, highlighting its mechanism of action, pharmacological properties, and potential clinical applications.

One of the key areas of interest in recent research is the compound's ability to modulate the activity of histone deacetylases (HDACs), a class of enzymes implicated in gene expression regulation. Studies have demonstrated that 2-Fluoro-N-hydroxypyridine-4-carboxamide exhibits selective inhibition of HDAC6, which plays a critical role in protein degradation and cellular stress responses. This selectivity is attributed to the unique structural features of the compound, including the fluorine substitution and the hydroxamic acid moiety, which enhance its binding affinity and specificity.

In vitro and in vivo studies have provided compelling evidence of the compound's efficacy in preclinical models of cancer and inflammatory diseases. For instance, a recent study published in the Journal of Medicinal Chemistry reported that 2-Fluoro-N-hydroxypyridine-4-carboxamide significantly reduced tumor growth in xenograft models of multiple myeloma by disrupting the aggresome pathway, a mechanism critical for cancer cell survival. Additionally, the compound showed minimal off-target effects, suggesting a favorable safety profile for further clinical development.

Beyond its anticancer potential, emerging research has explored the compound's utility in neurodegenerative diseases. A 2023 study in ACS Chemical Neuroscience revealed that 2-Fluoro-N-hydroxypyridine-4-carboxamide could attenuate neuroinflammation and improve cognitive function in animal models of Alzheimer's disease. The compound's ability to cross the blood-brain barrier and target HDAC6 in neuronal cells positions it as a promising candidate for treating central nervous system disorders.

Despite these promising findings, challenges remain in the clinical translation of 2-Fluoro-N-hydroxypyridine-4-carboxamide. Pharmacokinetic studies indicate that the compound has a relatively short half-life, necessitating the development of optimized formulations or prodrug strategies. Furthermore, ongoing research is investigating potential drug-drug interactions and long-term toxicity profiles to ensure its suitability for human use.

In conclusion, 2-Fluoro-N-hydroxypyridine-4-carboxamide (CAS: 1880041-66-6) represents a versatile and potent small molecule with broad therapeutic potential. Its selective inhibition of HDAC6 and favorable pharmacological properties make it a compelling candidate for further development in oncology, neurology, and immunology. Future research should focus on addressing the current limitations and advancing the compound through clinical trials to fully realize its therapeutic benefits.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)